Monday, 26 October 2026 · Amsterdam
Hospitality & Culinary
Media Platform
AMUSE.
Business

Weight-loss jabs push Heineken to rethink pub menus

A Heineken presentation seen by Reuters tells UK hospitality customers to promote half-pints and low-alcohol drinks as GLP-1 use grows.

A full pint of lager with a thick foam head on a worn wooden pub table
Photograph · Photo: Daniel Reche · Pexels · Pexels License

Heineken has warned UK hospitality customers that weight-loss jabs are starting to cut into beer sales, and told them to adapt their drinks menus before the trend goes further.

The warning comes in a company presentation, seen by Reuters, that Heineken recently sent to UK pub, bar and restaurant customers. It says GLP-1 drugs can suppress appetite and alcohol consumption through "fullness and fewer serves," and that the traditional multi-pint session could become harder to sustain as more drinkers use them.

Heineken's advice is specific: promote half-pints, promote low- and no-alcohol drinks, and pair drinks with small plates. The presentation warns that venues which do not adapt risk losing footfall and spend, not just swapping one serve size for another.

Less than £300 million of Britain's £14 billion pub beer trade already comes from no- and low-alcohol drinks.

Why Heineken is worried about weight-loss jabs

The numbers explain the nerves. Beer generated nearly £14 billion in sales across British pubs, bars and restaurants in the year to February 2026, according to Heineken's own UK data, in a year when UK hospitality posted its best month of 2026 in September. Less than £300 million of that came from no- and low-alcohol beer — a sliver of the category Heineken is now asking operators to push harder.

That sliver is growing on its own terms: low- and no-alcohol beer sales rose 12% in the first half of 2026, before GLP-1 use became a boardroom talking point. The jabs add urgency to a shift that was already under way.

How many drinkers are already on GLP-1

Research firm KAM Insight found that up to 7% of UK adults, almost four million people, were using GLP-1 drugs in 2025. Mintel puts the pool of interest wider still, with a quarter of UK adults saying they'd consider taking them. Neither firm has published the sample size behind those figures.

PwC data cited in the same reporting found that 61% of GLP-1 users spend less when dining out. Of those cutting back, 28% order less alcohol and 26% order fewer desserts — the two categories pubs and restaurants lean on hardest for margin.

A Heineken spokesperson — the brewer is separately in talks to buy Stonegate's pub estate — said the presentation was part of its regular engagement with UK hospitality businesses, and that it is seeing "changes in consumption behaviour" among GLP-1 users that it will keep monitoring into 2027.

For now, the ask is modest next to the scale of the trade: fewer full pints, more halves, a bit more food on the side. Whether that is enough is a question Heineken says it cannot yet answer.

Sources

Amuse Monthly

The best of the month,
once a month.

The openings of the month, the chefs to watch, the recipes and the figures that matter. Once a month in your inbox, five minutes, nothing else.

Sponsored slots are always labelled. Editorial is never for sale.

What lands in your inbox

  • The places worth booking this month
  • The opening everyone is talking about
  • The recipes of the month, from the kitchens we cover
  • The figures that matter, with their source